(Q36382590)

13 August 2017

1 reference

title

Insulin detemir: from concept to clinical experience (English)

1 reference

13 August 2017

1 reference

1 reference

Philip Home

1

1 reference

PubMed ID

16448327

13 August 2017

Peter Kurtzhals

series ordinal

2

1 reference

PubMed ID

16448327

13 August 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

Expert Opinion on Pharmacotherapy

13 August 2017

1 reference

13 August 2017

7

1 reference

13 August 2017

3

1 reference

13 August 2017

325-343

1 reference

Rapid-acting insulin secretagogues: a clinical need?

13 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Monomeric insulins and their experimental and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

New insulins in the treatment of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

The psychosocial impact of severe hypoglycemic episodes on spouses of patients with IDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Variability of insulin absorption and insulin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Double-blind crossover trial of isophane (NPH)- and lente-based insulin regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Insulin analogues and their potential in the management of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

A One-year, Randomised, Multicentre Trial Comparing Insulin Glargine with NPH Insulin in Combination with Oral Agents in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Crystal structure of a prolonged-acting insulin with albumin-binding properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Mode of transcapillary transport of insulin and insulin analog NN304 in dog hindlimb: evidence for passive diffusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Albumin binding of acylated insulin (NN304) does not deter action to stimulate glucose uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Continuous subcutaneous insulin infusion versus injection therapy: a randomized cross-over trial under usual diabetic clinic conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Intensive insulin therapy in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Insulin secretion in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Increase in plasma leptin and Lep mRNA concentrations by food intake is dependent on insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Novel forms of insulin delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

Monomeric insulins obtained by protein engineering and their medical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.3.325

21 January 2018

Identifiers

DOI

10.1517/14656566.7.3.325

1 reference

13 August 2017

1 reference

PubMed ID

16448327